Investigating the impact of clonal hematopoiesis on chemotherapy complications in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the role of Clonal Hematopoiesis of Indeterminate Significance (CHIP) in patients aged 60 and older who are diagnosed with lymphoma and undergoing chemotherapy. The research aims to determine if the presence of CHIP increases the risk of complications such as low blood counts, infections, and hospitalizations during and after chemotherapy treatment. By analyzing blood samples, the study seeks to identify the relationship between CHIP and chemotherapy-related adverse effects, potentially leading to tailored treatment strategies for older patients. The findings may enhance understanding of why some patients experience more severe complications than others.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of a lymphoma (ex: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's macroglobulinemia, anaplastic large cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and mantle cell lymphoma).
* Commencing first or second-line cytotoxic chemotherapy for lymphoma with or without rituximab \[ex: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), Fludarabine, fludarabine cyclophosphamide (FC), Bendamustine, cisplatin, cytarabine, dexamethasone (DHAP), etoposide, cytarabine, cisplatin, prednisone (ESHAP), gemcitabine, cisplatin and dexamethasone (GDP), Cladribine, Cyclophosphamide, Epirubicin, Vincristine, Prednisone (CEOP), dose-adjusted Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)\]

Exclusion Criteria:

* Pre-existing diagnosis of myeloid neoplasm
* Circulating lymphocyte count \> 10 x 109/L
* Significant uncontrolled renal or hepatic impairment \[\>1.5 x upper limit of normal (ULN) bilirubin, \>1.5 x ULN Alanine aminotransferase (ALT), \>1.5 x ULN creatinine\]
* HIV
* Active infection

Where it's running

• Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Rena Buckstein, MD, FRCPC — Sunnybrook Health Sciences Centre
• Study coordinator: Prasha Sasitharakumar, MHSc
• Email: prasha.sasitharakumar@sunnybrook.ca
• Phone: (416) 480-5000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of exercise training in lymphoma survivors

  This study is testing whether adding aerobic and resistance exercise to usual care can improve fitness and health for people who have survived lymphoma.

  Recruiting Norwegian School of Sport Sciences · Oslo and 1 other locations · NCT06270667

• Investigation of blood mutations in elderly lymphoma patients

  This study is testing how blood mutations affect older patients with B-cell Non-Hodgkin lymphoma during chemotherapy to see who might do better with standard treatments or newer options that have fewer side effects.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05245487

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.